-
JAMA Sub-issue: Discover blood markers to evaluate the efficacy of Alzheimer's disease drugs!
Time of Update: 2023-01-06
At baseline, plasma pTau217 levels in AD patients were significantly positively correlated with brain amyloid plaques and Tau protein deposition on Aβ and Tau PET imagingNext, the researchers analyzed changes in plasma biomarkers in AD patients after Donanemab treatment.
-
JAMA Sub-issue: Discover blood markers to evaluate the efficacy of Alzheimer's disease drugs!
Time of Update: 2023-01-06
At baseline, plasma pTau217 levels in AD patients were significantly positively correlated with brain amyloid plaques and Tau protein deposition on Aβ and Tau PET imagingNext, the researchers analyzed changes in plasma biomarkers in AD patients after Donanemab treatment.
-
-related leukocyte surface antigen markers to help the early hematological diagnosis of Alzheimer's disease
Time of Update: 2023-01-05
Written by - Huangdao Lord, Li Yifan is responsible for editing - Wang Sizhen, Fang Yiyi editing - Xia Leaf Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive impairmen
-
Neurology: The first large-scale prospective real-world study confirms that blood markers are feasible to predict Alzheimer's disease!
Time of Update: 2023-01-01
Studies have shown a correlation between AD markers detected in blood and cerebrospinal fluid/PET [5], blood phosphorylated tau protein can be used to distinguish AD from other neurodegenerative diseases, and blood markers are equally feasible for predicting the risk of AD-related dementia [6-7].
-
"Alzheimer's disease" marker – a hot project on the rise
Time of Update: 2022-11-25
Research backgroundAlzheimer's disease (AD) is an insidious and slow-degenerative disease that is the most common form of senile dementia, accounting for an estimated 60 to 80 percent of total dementi
-
Can classic markers of Alzheimer's disease help with early screening?
Time of Update: 2022-11-15
However, after correcting for age, sex and APOE alleles and corrected by Bonferroni, plasma t-tau and NfL in the AD group increased significantly compared with the CN group (p 。Fig. 1 Comparison of plasma biomarkers between AD group and CN groupCorrelation between plasma biomarkers and demographic characteristicsNext, the authors analyzed correlations between plasma biomarkers and demographic data, including age of onset (AAO), age at diagnosis, disease course, and level of education.
-
Front. Aging Neurosci: Alzheimer's disease-related markers associated with physical activity levels in cognitively normal older adults
Time of Update: 2022-08-12
Aging Neurosci to evaluate the relationship between habitual physical activity levels and brain amyloid deposition and AD -related blood biomarkers in (APOE) ε4 carriers and non-carriers .
-
Preventing Alzheimer's disease, this cholesterol marker has big implications
Time of Update: 2022-05-19
Researchers at the University of Southern California (USC) Keck Medical Center have found that the amount of high-density lipoprotein in the cerebrospinal fluid is related to cognitive performance in older adults and may have a protective effect against Alzheimer's disease .
-
The Lancet Neurol: Association of soluble TREM2 with other markers of autosomal dominant Alzheimer's disease and cognitive function
Time of Update: 2022-04-21
TREM2 is protective against Alzheimer's diseaseThe aim of this study was to investigate the dynamics of soluble TREM2 (as a biomarker of TREM2 signaling) and amyloid beta (aβ) deposition, taue-related pathology, neuroimaging during autosomal dominant Alzheimer's disease progression Correlations between biological markers and cognitive decline .
-
"Neuron" Alzheimer's disease: Inflammatory markers evident in early stages
Time of Update: 2022-01-24
In recent years, evidence has shown that the brain's immune system and related inflammatory processes -- also known as "neuro-inflammation" -- contribute significantly to the development of Alzheimer's disease .
-
Beijing Xuanwu Hospital: Alzheimer's disease has a marker?
Time of Update: 2021-12-03
In a study where the AD group and the control group were about the same age, the sensitivity analysis results of CSF sTREM2 level and AD risk .
775432Age Matching Is Essential for the Study of Cerebrospinal Fluid sTREM2 Levels and Alzheimer's Disease Risk: A Meta-Analysis.
-
Determination of early markers of diseases such as Alzheimer's disease
Time of Update: 2021-11-15
(Intern reporter Zhang Jiaxin) According to a paper recently published in the journal Science Translational Medicine, researchers at the Medical University of South Carolina and Harvard Medical University Beth Israel Deaconess Medical Center found that cis P- Tau is a toxic, non-degradable brain protein and an early marker of vascular dementia (VAD) and Alzheimer's disease (AD) .
-
Determination of early markers of diseases such as Alzheimer's disease
Time of Update: 2021-11-11
(Intern reporter Zhang Jiaxin) According to a paper recently published in the journal Science Translational Medicine, researchers at the Medical University of South Carolina and Harvard Medical University Beth Israel Deaconess Medical Center found that cis P- Tau is a toxic, non-degradable brain protein and an early marker of vascular dementia (VAD) and Alzheimer's disease (AD) .
-
Alzheimer Dementia: Alzheimer's disease, apolipoprotein B is a new marker of early tau pathology
Time of Update: 2021-10-09
The important significance of this study lies in the discovery: CSF apoB is significantly related to the early tau imbalance in asymptomatic subjects, and it has identified the high-risk population that is likely to develop visual and spatial cognitive decline over time .
-
JNNP: cerebrospinal fluid β-synuclein as an early diagnostic marker for Alzheimer's disease
Time of Update: 2021-01-16
addition, the findings confirm previous studies that have given mass spectrometry, i.e. increased levels of β-synuclein in CSF in AD and CJD patients, supporting its potential use as a synapse degeneration marker.
